Amrize price target lowered to $54 from $61 at RBC Capital

RBC Capital analyst Anthony Codling lowered the firm’s price target on Amrize (AMRZ) to $54 from $61 but keeps an Outperform rating on the shares. Much of the share price weakness following Q2 results could have been avoided, but Amrize is paying the price of keeping a low profile, the analyst tells investors in a research note. RBC adds however that the guidance debate is a distraction that may lead investors to miss out on an attractive entry point in the Amrize story.